Gossamer Bio Inc., a clinical biopharmaceutical company, has entered into a global collaboration agreement with the Chiesi Group to jointly develop seralutinib for the treatment of pulmonary arterial hypertension (PAH). This partnership aims to advance seralutinib as a potential first-in-class treatment option, with the companies focusing on Functional Class II and III PAH patients. The collaboration is currently centered on the ongoing Phase 3 PROSERA Study, which recently completed enrollment. This study is a critical step in evaluating the efficacy of seralutinib and is expected to yield topline results in February 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。